Study to Evaluate the Safety, Tolerability and Preliminary Antitumor Activity of INCB059872 in Patients with Relapsed/Refractory Ewing Sarcoma

Overview

About this study

The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of INCB059872 in participants with Ewing sarcoma who are refractory or relapsed from prior standard therapy and not eligible for further standard systemic therapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • The participant (or legally acceptable representative if applicable) provides written informed consent for the study.
  • The participant must be 12 years of age or older, at the time of signing the informed consent.
  • Have histologically or cytologically confirmed diagnosis of Ewing sarcoma and have progressed on or after standard therapies.
  • The participant must not be a candidate for potentially curative therapy or standard-of-care approved therapy.
  • Have measurable disease by CT or MRI based on RECIST 1.1 as determined by site radiology.
  • ECOG performance status 0 to 2.
  • Baseline archival tumor specimen available or if an archived sample is not available, a predose core tumor biopsy will be required in order to enter the study. Archived specimens must be an FFPE tumor block with sufficient tumor for 15 consecutive sections or 15 unstained slides from biopsy or resection of primary tumor that is preferably ≤ 1 year old and obtained after completion of last treatment. Fine needle aspiration and/or brushing biopsy are not acceptable. If a fresh biopsy is not feasible, discuss with sponsor medical monitor.
  • Willingness to avoid pregnancy or fathering children based on the criteria below.
    • Male participants must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through 90 days after the last dose of study drug(s) and refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participant and their understanding confirmed.
    • Woman of nonchildbearing potential (i.e., surgically sterile with a hysterectomy and/or bilateral oophorectomy OR ≥ 12 months of amenorrhea).
    • Woman of childbearing potential who has a negative serum pregnancy test at screening and negative urine pregnancy test before the first dose on Day 1 and who agrees to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through safety follow-up. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participant and their understanding confirmed.

Exclusion Criteria:

  • Receipt of anticancer medications, anticancer therapies, or investigational drugs within the following interval before the first administration of study drug (requirement may be waived with medical monitor approval):
    • < 6 weeks for mitomycin or nitrosoureas;
    • < 5 half-lives or 14 days, whichever is longer, for any investigational agent (for any indication);
    • < 5 half-lives for all other anticancer medications (unless approved by sponsor);
    • < 4 weeks for immunotherapy or antibody therapy.
  • Participants must have recovered (≤ Grade 2 or at pretreatment baseline) from AEs from previously administered therapies except for stable chronic toxicities (≤ Grade 2) not expected to resolve.
  • Concurrent anticancer therapy (e.g., chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, investigational therapy, or tumor embolization).
  • Untreated brain or CNS metastases or brain/CNS metastases that have progressed (e.g., evidence of new or enlarging brain metastasis or new neurological symptoms attributable to brain/CNS metastases). Participants with previously treated and clinically stable brain/CNS metastases who are receiving concomitant corticosteroids must be on a stable or decreasing dose for at least 2 weeks (equivalent to ≤ 10 mg/day) or off of all corticosteroids for at least 2 weeks before the first dose of study treatment.
  • Prior radiotherapy within 2 weeks of study treatment. Participants must have recovered from all radiation-related toxicities, including radiation pneumonitis, and not require corticosteroids. Evidence of fibrosis within a radiation field from prior radiotherapy is permitted with medical monitor approval. A 1-week washout period is permitted for palliative radiation to non-CNS disease with medical monitor approval.
  • Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.
  • Unless approved by the medical monitor, receipt of autologous hematopoietic stem cell transplant within 3 months before receiving the first dose of study drug(s), receipt of allogeneic stem cell transplant within 6 months before receiving the first dose of study drug(s), or active graft-versus-host disease after transplant, or receipt of immunosuppressive therapy following allogeneic transplant within 2 weeks of Cycle 1 Day 1 (prednisone ≤ 10 mg/day is allowed).
  • Participants with laboratory values at screening, without transfusions and hematopoietic growth factor support, defined below (transfusions are permitted to achieve required hemoglobin level that remains above ≥ 9 g/L for at least 2 weeks).
    • Hematology
    • Platelet count 
      • < 100 × 10^9/L
    • Hemoglobin
      • < 9 g/L
    • ANC
      • < 1.5 × 10^9/L
    • Hepatic
      • ALT
        • > 2.5 × ULN, > 5 × ULN in the presence of liver metastases  
      • AST
        • > 2.5 × ULN, > 5 × ULN in the presence of liver metastases
    • Total bilirubin
      • > 1.5 × ULN or > 3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia
    • Renal 
    • Serum creatinine clearance
      • ≤ 40 mL/minute based on Cockcroft-Gault formula
  • History or evidence of bleeding disorder or active clinically significant bleeding requiring medical intervention.
  • Has a significant concurrent, uncontrolled medical condition, including but not limited to the following:
  • GI
    • Inability of the participant to swallow and retain oral medication.
  • Cardiovascular
    • Clinically significant or uncontrolled cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, and unstable arrhythmia requiring therapy unless approved by medical monitor/sponsor.
    • History or presence of an abnormal ECG, which, in the investigator's opinion, is clinically meaningful. A screening QTcF interval > 470 ms is excluded. For participants with an intraventricular conduction delay (QRS interval ≥ 120 ms), the JTc interval may be used in place of the QTc with sponsor approval. Participants with left bundle branch block are excluded.
  • Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment, unless approved by medical monitor.
  • Prior treatment with an LSD1 inhibitor for any indication.
  • Current use of prohibited medication.
  • Inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator.
  • Inadequate recovery from toxicity and/or complications from a major surgery before starting therapy.
  • Women who are pregnant or breastfeeding or participants expecting to conceive or father children within the projected duration of the study, starting with the screening visit through completion of safety follow-up visit.
  • Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
  • Inability of the participant (or parent, guardian, or legally authorized representative) to comprehend or unwillingness to sign the ICF.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Steven Attia, D.O.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Steven Attia, D.O.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Steven Attia, D.O.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20442764

Mayo Clinic Footer